Real‑World GLP‑1 Results: India

A Delhi hospital study found that more than 4 in 10 Indian patients on newer weight-loss injections lost at least 10% of their body weight in routine care. (timesofindia.indiatimes.com) Doctors at Max Super Speciality Hospital, Saket, tracked 150 overweight and obese adults and reported the results in the *Indian Journal of Endocrinology and Metabolism*, according to The Times of India on April 11, 2026. (timesofindia.indiatimes.com) Patients lost about 8% of body weight on average in six months, or roughly 6 to 10 kilograms, and nearly three-fourths lost at least 5%, the threshold doctors often use for measurable health gains. (timesofindia.indiatimes.com) These drugs mimic or amplify gut hormones that slow stomach emptying and reduce appetite, and the newer shots in this report included semaglutide and tirzepatide. Patients on tirzepatide lost weight faster than those on semaglutide in the Delhi study. (timesofindia.indiatimes.com) The split inside the study was sharp: people without diabetes lost almost twice as much weight as people with diabetes, and younger patients and first-time users responded faster. Most patients who reached the 10% mark did so in about 9 to 10 months. (timesofindia.indiatimes.com) That pattern fits broader research. A 2025 review in *Diabetes, Obesity and Metabolism* found real-world weight loss with glucagon-like peptide-1 receptor agonists usually runs below clinical-trial results, in part because 20% to 50% of patients stop within the first year or take lower doses. (pmc.ncbi.nlm.nih.gov) The India data lands as these drugs spread quickly in the country. Eli Lilly launched Mounjaro, the brand name for tirzepatide, in India in March 2025, and Novo Nordisk launched Wegovy, the brand name for semaglutide 2.4 milligrams, in major Indian cities on June 24, 2025. (economictimes.indiatimes.com) Price remains a constraint. The Economic Times reported that Mounjaro was selling in India at ₹3,500 for a 2.5 milligram vial and ₹4,375 for a 5 milligram vial, or roughly ₹14,000 to ₹17,500 a month depending on dose. (economictimes.indiatimes.com) Side effects in the Delhi study were mostly nausea, bloating, and constipation early in treatment, and doctors said they were manageable enough that patients did not stop therapy. (timesofindia.indiatimes.com) The World Health Organization’s 2025 guideline says these medicines can produce clinically meaningful weight loss, but it recommends using them with intensive behavioral treatment and warns that long-term access, affordability, and health-system capacity still shape who benefits. (jamanetwork.com)